RxDoctor Payments Data

Miranda Thomas

Family · Hagerstown, MDNPI 1427512318

Payments from drug & device makers

$5,332in general payments, 2019–2025

Across 254 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$644
  • Astellas Pharma US Inc$605
  • Pfizer$516
  • Bayer$493
  • Sumitomo Pharma America, Inc.$421
  • Endo Pharmaceuticals Inc.$375
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,95893%
  • Education$3747%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,332 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$212,747
Medicare patients
1,070
Services billed
4,614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron214$208,516
MyrbetriqMirabegron227$207,453
Tamsulosin Hcl1,084$23,402
NitrofurantoinNitrofurantoin Macrocrystal188$7,379
Finasteride425$6,867
Methenamine Hippurate64$5,509
Potassium Citrate ErPotassium Citrate61$5,202
Fosfomycin Tromethamine15$4,451
Estradiol41$2,921
Oxybutynin Chloride ErOxybutynin Chloride95$2,450
Solifenacin Succinate69$2,370
Testosterone22$2,294
Dutasteride31$2,292
Trospium Chloride20$2,136
Tolterodine Tartrate ErTolterodine Tartrate39$1,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$421$208,516214 claims
Astellas Pharma US IncMyrbetriq$605$207,453227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.

Other family in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →